Retrospective Case-Control Study of REGEN-COV (casirivimab and imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan ® Database

Conclusion Patients with cancer treated with REGEN-COV experienced a decreased risk for hospitalization, hospitalization duration, and total COVID-19-related costs. Patients with cancer were at a higher risk of being hospitalized for COVID-19 than were those without cancer. The use of neutralizing antibody therapy may reduce the risk of severe COVID-19 infection for patients with cancer with an otherwise high risk. Future replication studies should be conducted using other databases that include Medicaid users and other insured persons for comparison and validation.PMID:37666220 | DOI:10.1159/000533614
Source: Oncology - Category: Cancer & Oncology Authors: Source Type: research